Navigation Links
Research on China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2013-2017

London (PRWEB) November 19, 2013

“Research on China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2013-2017” mainly conducts in-depth analysis on the external environment, market operation, import &export, as well as other aspects of China’s IVD reagent industry, and also summaries the latest development state in 2012 of key domestic enterprises, and finally forecasts the future industrial development. The information can provide investors with decision-making reference.

IVD reagent industry is an emerging industry in China, the start is late and the development is relatively backward compares with occidental countries. According to the data provided by IVD Special Committee, there are 300 to 400 IVD reagent manufacturing enterprises in China, of which, 200 enterprises own above designated scale; however, only about 20 enterprises have the ability to achieve annual sales income of more than CNY 100 million; the enterprises are in small scale in general and the variety is less.

In 2012, the scale of China’s IVD market has reached CNY 19 billion, of which, the scale of IVD reagent market was CNY 13.8 billion.

In recent years, China’s IVD reagent industry has entered the development phase from the introduction stage, and the market demand increased rapidly; domestic enterprises grasped opportunities by virtue of the advantages of high performance cost ratio and closer to the local market, and seized the market share constantly; thus, the market pattern which was dominated by the imported products is breaking down gradually. With the strengthening of R&D investment and the improvement of products quality, a number of local enterprises with relatively strong strength have appeared in China’s IVD reagent industry, which concentrated in biochemical, immune and molecular diagnoses fields, some products have owned the ability to compete with the international giants.

The state policy encourages the competitive enterprises to strengthen their strength. In 2013, a series of policies which target to improve industry standard and threshold will enter the substantive operation stage, which will accelerate the elimination of small enterprises and improve the industry concentration ratio, industrial consolidation is the development trend, and the enterprises with capital, technology and scale advantages will win gradually.

In recent years, due to the continued sluggishness of European and American pharmaceutical market, the international giants target on the market expansion brought by China’s new medical reform, and entered China’s market in succession; after the China-oriented R&D center transfer, these powerful enterprises began to compete with China’s enterprises in the low and medium-end markets through mergers, acquisitions, capital increase and production expansion; therefore, the competitive enterprises in China’s diagnostic reagent subdivided industries will face more sever competitions.

Please note: The report is Chinese version. It will provide the English version in two business days.

1. Overview of Diagnostic Reagent Industry
1.1 Definition and Classification
1.1.1 Definition and Classification of Biological Products
1.1.2 Definition and Classification of IVD Reagents
1.2 Development History
1.3 Industry Chain
1.4 Overview of Main Sub-industries
1.4.1 Biochemical Diagnostic Reagent Industry
1.4.2 Immune Diagnostic Reagent
1.4.3 Molecular Diagnostic Reagent

2. Operating Environment of China’s IVD Reagent Industry
2.1 Development Overview of Global IVD Reagent Industry
2.2 Development Overview of China’s Bio-pharmaceutical Industry
2.3 Related Industry Management and Policy
2.3.1 Industry Competent Departments
2.3.2 Industry Supervision System
2.3.3 Main Laws and Regulations
2.3.4 Main Industry Policies

3. Operation State of China’s IVD Reagent Market
3.1 Development Status
3.2 Demand
3.2.1 Overall Market Demand
3.2.2 Development Trend of Main Varieties
3.3 Competitive Landscape
3.4 Barriers to Entry
3.4.1 Technological Barrier
3.4.2 Quality and Brand Barrier
3.4.3 Marketing Channel Barrier
3.4.4 Market Access Barrier
3.5 Profit Level and Changing Trend
3.6 Adverse Factors for the Industry Development
3.6.1 Low Market Concentration Ratio; Serious Product homogeneity
3.6.2 Relatively Low Overall R&D Investment Level
3.6.3 International Giants Occupy Dominant Positions in China’s High-end Market
3.7 Technological Level and Business Model
3.7.1 Technological Level and Development Trend
3.7.2 Characteristics of Business Model
3.8 Periodicity, Regional Character and Seasonal Character
3.8.1 Periodicity
3.8.2 Regional Character
3.8.3 Seasonal Character
3.9 Relevance and Influence of Upstream Industries and Downstream Industries to the IVD Reagent Industry
3.9.1 Upstream Raw Materials Mainly Depend on Imports
3.9.2 Downstream Demands Present Rigidity
3.9.3 Relevance with the IVD Instrument Industry

4. Import and Export of China’s IVD Reagent Industry
4.1 Import
4.2 Export

5. Key Manufacturers in China’s IVD Reagent Industry
5.1 Shanghai Kehua Bio-engineering Co., Ltd.
5.1.1 Company Profile
5.1.2 Operation
5.1.3 Core Competitiveness
5.1.4 R&D Projects and Business Plan, 2013
5.2 DAAN Gene Co., Ltd.
5.2.1 Company Profile
5.2.2 Business Development, 2012
5.2.3 Main Business Composition, 2012
5.2.4 Core Competitiveness
5.3 Shanghai Fosun Pharmaceutical (Group) CO., Ltd.
5.3.1 Company Profile
5.3.2 Main Business Composition
5.3.3 Development of Medical Diagnosis and Medical Apparatus and Instruments Business
5.4 BioSino Bio-technology and Science Inc.
5.4.1 Company Profile
5.4.2 Operation
5.5 Beijing Leadman Biochemistry Co., Ltd.
5.5.1 Company Profile
5.5.2 Operation
5.5.3 Main Business Composition
5.6 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
5.6.1 Company Profile
5.6.2 Operation
5.6.3 Products Condition

6. Future Development of China’s IVD Reagent Industry
6.1 Development Trend
6.2 Opportunity
6.3 Forecast of Market Scale Growth, 2013-2017

Companies Mentioned

Shanghai Kehua Bio-engineering Co., Ltd.
DAAN Gene Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) CO., Ltd.
BioSino Bio-technology and Science Inc.
Beijing Leadman Biochemistry Co., Ltd.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Read the full report:

Research on China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2013-2017

For more information:
Sarah Smith
Research Advisor at
Tel: +44 208 816 85 48

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
2. NIH awards $20 million over 5 years to train next generation of global health researchers
3. Researchers develop a new cell and animal model of inflammatory breast cancer
4. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
5. Sexually abused boys at risk for more unsafe sex: UBC research
6. Researchers Find Gene Mutations That May Be a Key to Autism
7. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
8. Researchers find evidence of banned antibiotics in poultry products
9. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
10. Scientific session and new research highlights
11. NJ stroke researchers report advances in spatial neglect research at AAN Conference
Post Your Comments:
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Association of Poison Control Centers’ National Poison Data System (NPDS) reveals that in ... managed almost 3 million cases, over two million of which were human exposure ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage ... effective immediately. , “We are pleased to announce our expanded distribution agreement ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Solutions, announced at the Radiology Society of North America (RSNA) annual meeting, being ... over 60% growth from 2014. Throughout 2015, the company has completed installations ...
(Date:11/30/2015)... ... 30, 2015 , ... Holcomb – Kreithen Plastic Surgery ... practices in Florida, is proud to announce that Dr. Joshua Kreithen, one of ... Inc., a Johnson & Johnson Company. , Ethicon is a global medical device ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and Novus ... technology for soft tissue repair in the US via Insightra’s national direct sales ... mesh intended to support and reinforce soft tissue for 6-9 months before absorbing ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... , Nov. 29, 2015  Strengthening its leadership ... PHG, AEX: PHIA) today announced IntelliSpace Portal 8.0 ... analytics and visualization platform that helps radiologists detect, diagnose ... 2015 Radiological Society of North America Annual Meeting ... IntelliSpace Portal 8.0 helps address the changing demands in ...
(Date:11/29/2015)... , Nov. 29, 2015  At this year,s ... to experience the most complete mobile C-arm portfolio with ... is Ziehm Vision RFD 3D, the world,s only 3D ... edge length per scan volume. In addition, Ziehm Imaging ... motorized mobile C-arm in four axes which is ideally ...
(Date:11/29/2015)... 29, 2015 CIVCO Medical Solutions will ... the Radiological Society of North America ... November 29 – December 4, 2015. ... offer customers unrivaled versatility, enhanced user experience and ... --> ...
Breaking Medicine Technology: